nodes	percent_of_prediction	percent_of_DWPC	metapath
Cladribine—multiple sclerosis—amyotrophic lateral sclerosis	0.692	1	CtDrD
Cladribine—ABCG2—Riluzole—amyotrophic lateral sclerosis	0.168	1	CbGbCtD
Cladribine—PNP—tongue—amyotrophic lateral sclerosis	0.00321	0.0796	CbGeAlD
Cladribine—Cardiac murmur—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0484	CcSEcCtD
Cladribine—POLE4—embryo—amyotrophic lateral sclerosis	0.00279	0.069	CbGeAlD
Cladribine—POLE2—embryo—amyotrophic lateral sclerosis	0.00244	0.0604	CbGeAlD
Cladribine—NR5A1—hindbrain—amyotrophic lateral sclerosis	0.00209	0.0519	CbGeAlD
Cladribine—Lymphopenia—Riluzole—amyotrophic lateral sclerosis	0.00179	0.0293	CcSEcCtD
Cladribine—Cholecystitis—Riluzole—amyotrophic lateral sclerosis	0.0016	0.0261	CcSEcCtD
Cladribine—Polyp—Riluzole—amyotrophic lateral sclerosis	0.00151	0.0246	CcSEcCtD
Cladribine—Blepharitis—Riluzole—amyotrophic lateral sclerosis	0.00149	0.0244	CcSEcCtD
Cladribine—Oral candidiasis—Riluzole—amyotrophic lateral sclerosis	0.00144	0.0236	CcSEcCtD
Cladribine—Cyst—Riluzole—amyotrophic lateral sclerosis	0.00137	0.0224	CcSEcCtD
Cladribine—POLE3—embryo—amyotrophic lateral sclerosis	0.00135	0.0335	CbGeAlD
Cladribine—POLE4—nervous system—amyotrophic lateral sclerosis	0.00134	0.0332	CbGeAlD
Cladribine—Ileus—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0212	CcSEcCtD
Cladribine—Thrombosis—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0212	CcSEcCtD
Cladribine—Interstitial lung disease—Riluzole—amyotrophic lateral sclerosis	0.0013	0.0212	CcSEcCtD
Cladribine—POLE4—central nervous system—amyotrophic lateral sclerosis	0.00129	0.0319	CbGeAlD
Cladribine—Neuritis—Riluzole—amyotrophic lateral sclerosis	0.00123	0.0201	CcSEcCtD
Cladribine—NR5A1—brainstem—amyotrophic lateral sclerosis	0.0012	0.0297	CbGeAlD
Cladribine—Myocardial ischaemia—Riluzole—amyotrophic lateral sclerosis	0.00114	0.0187	CcSEcCtD
Cladribine—Petechiae—Riluzole—amyotrophic lateral sclerosis	0.00111	0.0182	CcSEcCtD
Cladribine—POLE—embryo—amyotrophic lateral sclerosis	0.00103	0.0256	CbGeAlD
Cladribine—POLE4—brain—amyotrophic lateral sclerosis	0.00102	0.0253	CbGeAlD
Cladribine—Bone disorder—Riluzole—amyotrophic lateral sclerosis	0.00102	0.0166	CcSEcCtD
Cladribine—Cellulitis—Riluzole—amyotrophic lateral sclerosis	0.00101	0.0165	CcSEcCtD
Cladribine—Blood bilirubin increased—Riluzole—amyotrophic lateral sclerosis	0.00097	0.0159	CcSEcCtD
Cladribine—Pulmonary embolism—Riluzole—amyotrophic lateral sclerosis	0.000917	0.015	CcSEcCtD
Cladribine—RRM2B—medulla oblongata—amyotrophic lateral sclerosis	0.000914	0.0226	CbGeAlD
Cladribine—Injection site reaction—Riluzole—amyotrophic lateral sclerosis	0.000912	0.0149	CcSEcCtD
Cladribine—Depressed level of consciousness—Riluzole—amyotrophic lateral sclerosis	0.000886	0.0145	CcSEcCtD
Cladribine—Candida infection—Riluzole—amyotrophic lateral sclerosis	0.000876	0.0143	CcSEcCtD
Cladribine—POLE3—medulla oblongata—amyotrophic lateral sclerosis	0.000864	0.0214	CbGeAlD
Cladribine—Aplastic anaemia—Riluzole—amyotrophic lateral sclerosis	0.000861	0.0141	CcSEcCtD
Cladribine—RRM2—embryo—amyotrophic lateral sclerosis	0.000849	0.021	CbGeAlD
Cladribine—Neoplasm—Riluzole—amyotrophic lateral sclerosis	0.000829	0.0136	CcSEcCtD
Cladribine—Ecchymosis—Riluzole—amyotrophic lateral sclerosis	0.000829	0.0136	CcSEcCtD
Cladribine—RRM2B—spinal cord—amyotrophic lateral sclerosis	0.000815	0.0202	CbGeAlD
Cladribine—Sepsis—Riluzole—amyotrophic lateral sclerosis	0.000796	0.013	CcSEcCtD
Cladribine—Phlebitis—Riluzole—amyotrophic lateral sclerosis	0.000773	0.0126	CcSEcCtD
Cladribine—POLE3—spinal cord—amyotrophic lateral sclerosis	0.00077	0.0191	CbGeAlD
Cladribine—Vascular purpura—Riluzole—amyotrophic lateral sclerosis	0.000744	0.0122	CcSEcCtD
Cladribine—PNP—nervous system—amyotrophic lateral sclerosis	0.00074	0.0183	CbGeAlD
Cladribine—PNP—central nervous system—amyotrophic lateral sclerosis	0.000712	0.0176	CbGeAlD
Cladribine—Atrial fibrillation—Riluzole—amyotrophic lateral sclerosis	0.000703	0.0115	CcSEcCtD
Cladribine—Purpura—Riluzole—amyotrophic lateral sclerosis	0.000691	0.0113	CcSEcCtD
Cladribine—RRM2B—nervous system—amyotrophic lateral sclerosis	0.000687	0.017	CbGeAlD
Cladribine—Arthritis—Riluzole—amyotrophic lateral sclerosis	0.000685	0.0112	CcSEcCtD
Cladribine—Cardiac failure—Riluzole—amyotrophic lateral sclerosis	0.000682	0.0112	CcSEcCtD
Cladribine—RRM2B—central nervous system—amyotrophic lateral sclerosis	0.000661	0.0164	CbGeAlD
Cladribine—POLE3—nervous system—amyotrophic lateral sclerosis	0.000649	0.0161	CbGeAlD
Cladribine—RRM2B—cerebellum—amyotrophic lateral sclerosis	0.000646	0.016	CbGeAlD
Cladribine—NR5A1—nervous system—amyotrophic lateral sclerosis	0.000629	0.0156	CbGeAlD
Cladribine—Ataxia—Riluzole—amyotrophic lateral sclerosis	0.000626	0.0102	CcSEcCtD
Cladribine—POLE3—central nervous system—amyotrophic lateral sclerosis	0.000625	0.0155	CbGeAlD
Cladribine—POLE3—cerebellum—amyotrophic lateral sclerosis	0.000611	0.0151	CbGeAlD
Cladribine—NR5A1—central nervous system—amyotrophic lateral sclerosis	0.000606	0.015	CbGeAlD
Cladribine—NR5A1—cerebellum—amyotrophic lateral sclerosis	0.000592	0.0147	CbGeAlD
Cladribine—Muscular weakness—Riluzole—amyotrophic lateral sclerosis	0.000587	0.0096	CcSEcCtD
Cladribine—PNP—brain—amyotrophic lateral sclerosis	0.000565	0.014	CbGeAlD
Cladribine—Abdominal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000552	0.00902	CcSEcCtD
Cladribine—DCK—embryo—amyotrophic lateral sclerosis	0.000548	0.0136	CbGeAlD
Cladribine—Pancytopenia—Riluzole—amyotrophic lateral sclerosis	0.000546	0.00893	CcSEcCtD
Cladribine—Neutropenia—Riluzole—amyotrophic lateral sclerosis	0.000538	0.0088	CcSEcCtD
Cladribine—RRM2B—brain—amyotrophic lateral sclerosis	0.000525	0.013	CbGeAlD
Cladribine—Pneumonia—Riluzole—amyotrophic lateral sclerosis	0.000516	0.00844	CcSEcCtD
Cladribine—Infestation—Riluzole—amyotrophic lateral sclerosis	0.000513	0.00839	CcSEcCtD
Cladribine—Infestation NOS—Riluzole—amyotrophic lateral sclerosis	0.000513	0.00839	CcSEcCtD
Cladribine—Urinary tract infection—Riluzole—amyotrophic lateral sclerosis	0.000499	0.00815	CcSEcCtD
Cladribine—POLE3—brain—amyotrophic lateral sclerosis	0.000496	0.0123	CbGeAlD
Cladribine—POLE—nervous system—amyotrophic lateral sclerosis	0.000495	0.0123	CbGeAlD
Cladribine—Hepatobiliary disease—Riluzole—amyotrophic lateral sclerosis	0.000485	0.00793	CcSEcCtD
Cladribine—Epistaxis—Riluzole—amyotrophic lateral sclerosis	0.000484	0.00791	CcSEcCtD
Cladribine—NR5A1—brain—amyotrophic lateral sclerosis	0.000481	0.0119	CbGeAlD
Cladribine—POLE—central nervous system—amyotrophic lateral sclerosis	0.000477	0.0118	CbGeAlD
Cladribine—POLE—cerebellum—amyotrophic lateral sclerosis	0.000466	0.0115	CbGeAlD
Cladribine—Haemoglobin—Riluzole—amyotrophic lateral sclerosis	0.000463	0.00757	CcSEcCtD
Cladribine—Haemorrhage—Riluzole—amyotrophic lateral sclerosis	0.000461	0.00753	CcSEcCtD
Cladribine—Pharyngitis—Riluzole—amyotrophic lateral sclerosis	0.000457	0.00747	CcSEcCtD
Cladribine—Urinary tract disorder—Riluzole—amyotrophic lateral sclerosis	0.000455	0.00744	CcSEcCtD
Cladribine—Oedema peripheral—Riluzole—amyotrophic lateral sclerosis	0.000454	0.00742	CcSEcCtD
Cladribine—Connective tissue disorder—Riluzole—amyotrophic lateral sclerosis	0.000453	0.0074	CcSEcCtD
Cladribine—Urethral disorder—Riluzole—amyotrophic lateral sclerosis	0.000451	0.00738	CcSEcCtD
Cladribine—RRM1—medulla oblongata—amyotrophic lateral sclerosis	0.000451	0.0112	CbGeAlD
Cladribine—Erythema multiforme—Riluzole—amyotrophic lateral sclerosis	0.000435	0.00712	CcSEcCtD
Cladribine—Eye disorder—Riluzole—amyotrophic lateral sclerosis	0.00043	0.00704	CcSEcCtD
Cladribine—Cardiac disorder—Riluzole—amyotrophic lateral sclerosis	0.000427	0.00699	CcSEcCtD
Cladribine—Angiopathy—Riluzole—amyotrophic lateral sclerosis	0.000418	0.00683	CcSEcCtD
Cladribine—Immune system disorder—Riluzole—amyotrophic lateral sclerosis	0.000416	0.0068	CcSEcCtD
Cladribine—Mediastinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000415	0.00679	CcSEcCtD
Cladribine—Chills—Riluzole—amyotrophic lateral sclerosis	0.000413	0.00676	CcSEcCtD
Cladribine—Arrhythmia—Riluzole—amyotrophic lateral sclerosis	0.000411	0.00673	CcSEcCtD
Cladribine—RRM2—nervous system—amyotrophic lateral sclerosis	0.000408	0.0101	CbGeAlD
Cladribine—Alopecia—Riluzole—amyotrophic lateral sclerosis	0.000407	0.00665	CcSEcCtD
Cladribine—Mental disorder—Riluzole—amyotrophic lateral sclerosis	0.000403	0.0066	CcSEcCtD
Cladribine—RRM1—spinal cord—amyotrophic lateral sclerosis	0.000402	0.00996	CbGeAlD
Cladribine—POLA1—cerebellum—amyotrophic lateral sclerosis	0.000402	0.00995	CbGeAlD
Cladribine—Malnutrition—Riluzole—amyotrophic lateral sclerosis	0.000401	0.00656	CcSEcCtD
Cladribine—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.000395	0.00646	CcSEcCtD
Cladribine—RRM2—central nervous system—amyotrophic lateral sclerosis	0.000393	0.00973	CbGeAlD
Cladribine—Back pain—Riluzole—amyotrophic lateral sclerosis	0.000388	0.00634	CcSEcCtD
Cladribine—POLE—brain—amyotrophic lateral sclerosis	0.000379	0.00938	CbGeAlD
Cladribine—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.000372	0.00608	CcSEcCtD
Cladribine—Anaemia—Riluzole—amyotrophic lateral sclerosis	0.000371	0.00606	CcSEcCtD
Cladribine—Malaise—Riluzole—amyotrophic lateral sclerosis	0.000362	0.00591	CcSEcCtD
Cladribine—DCK—medulla oblongata—amyotrophic lateral sclerosis	0.00035	0.00868	CbGeAlD
Cladribine—Cough—Riluzole—amyotrophic lateral sclerosis	0.00035	0.00572	CcSEcCtD
Cladribine—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00558	CcSEcCtD
Cladribine—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00558	CcSEcCtD
Cladribine—Arthralgia—Riluzole—amyotrophic lateral sclerosis	0.000341	0.00558	CcSEcCtD
Cladribine—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00034	0.00556	CcSEcCtD
Cladribine—Unspecified disorder of skin and subcutaneous tissue—Riluzole—amyotrophic lateral sclerosis	0.000339	0.00554	CcSEcCtD
Cladribine—RRM1—nervous system—amyotrophic lateral sclerosis	0.000339	0.00839	CbGeAlD
Cladribine—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.000337	0.00551	CcSEcCtD
Cladribine—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.00033	0.00539	CcSEcCtD
Cladribine—Oedema—Riluzole—amyotrophic lateral sclerosis	0.000327	0.00535	CcSEcCtD
Cladribine—POLA1—brain—amyotrophic lateral sclerosis	0.000326	0.00808	CbGeAlD
Cladribine—RRM1—central nervous system—amyotrophic lateral sclerosis	0.000326	0.00808	CbGeAlD
Cladribine—Infection—Riluzole—amyotrophic lateral sclerosis	0.000325	0.00532	CcSEcCtD
Cladribine—Nervous system disorder—Riluzole—amyotrophic lateral sclerosis	0.000321	0.00525	CcSEcCtD
Cladribine—Thrombocytopenia—Riluzole—amyotrophic lateral sclerosis	0.00032	0.00524	CcSEcCtD
Cladribine—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.000319	0.00522	CcSEcCtD
Cladribine—RRM1—cerebellum—amyotrophic lateral sclerosis	0.000319	0.0079	CbGeAlD
Cladribine—Skin disorder—Riluzole—amyotrophic lateral sclerosis	0.000318	0.0052	CcSEcCtD
Cladribine—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.000316	0.00517	CcSEcCtD
Cladribine—DCK—spinal cord—amyotrophic lateral sclerosis	0.000312	0.00774	CbGeAlD
Cladribine—Anorexia—Riluzole—amyotrophic lateral sclerosis	0.000312	0.0051	CcSEcCtD
Cladribine—RRM2—brain—amyotrophic lateral sclerosis	0.000312	0.00772	CbGeAlD
Cladribine—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.000306	0.005	CcSEcCtD
Cladribine—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.000298	0.00487	CcSEcCtD
Cladribine—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.000296	0.00484	CcSEcCtD
Cladribine—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.000294	0.0048	CcSEcCtD
Cladribine—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.000292	0.00477	CcSEcCtD
Cladribine—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.000291	0.00476	CcSEcCtD
Cladribine—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.000284	0.00465	CcSEcCtD
Cladribine—Gastrointestinal disorder—Riluzole—amyotrophic lateral sclerosis	0.000282	0.00462	CcSEcCtD
Cladribine—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.000282	0.00461	CcSEcCtD
Cladribine—Pain—Riluzole—amyotrophic lateral sclerosis	0.00028	0.00458	CcSEcCtD
Cladribine—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00028	0.00458	CcSEcCtD
Cladribine—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00027	0.00441	CcSEcCtD
Cladribine—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.000268	0.00437	CcSEcCtD
Cladribine—DCK—nervous system—amyotrophic lateral sclerosis	0.000263	0.00652	CbGeAlD
Cladribine—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00026	0.00425	CcSEcCtD
Cladribine—SLC22A2—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.000259	0.00681	CbGpPWpGaD
Cladribine—RRM1—brain—amyotrophic lateral sclerosis	0.000259	0.00642	CbGeAlD
Cladribine—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.000259	0.00423	CcSEcCtD
Cladribine—Body temperature increased—Riluzole—amyotrophic lateral sclerosis	0.000259	0.00423	CcSEcCtD
Cladribine—RRM2B—DNA Damage Response—CASP3—amyotrophic lateral sclerosis	0.000257	0.00676	CbGpPWpGaD
Cladribine—DCK—central nervous system—amyotrophic lateral sclerosis	0.000253	0.00628	CbGeAlD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—CASP3—amyotrophic lateral sclerosis	0.000249	0.00653	CbGpPWpGaD
Cladribine—DCK—cerebellum—amyotrophic lateral sclerosis	0.000248	0.00614	CbGeAlD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	0.000245	0.00643	CbGpPWpGaD
Cladribine—SLC22A1—Amine compound SLC transporters—SLC6A1—amyotrophic lateral sclerosis	0.000242	0.00635	CbGpPWpGaD
Cladribine—Hypersensitivity—Riluzole—amyotrophic lateral sclerosis	0.000241	0.00394	CcSEcCtD
Cladribine—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.000235	0.00384	CcSEcCtD
Cladribine—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.000231	0.00379	CcSEcCtD
Cladribine—SLC22A1—nervous system—amyotrophic lateral sclerosis	0.000224	0.00556	CbGeAlD
Cladribine—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.000224	0.00366	CcSEcCtD
Cladribine—SLC22A2—Neurotransmitter Release Cycle—CHAT—amyotrophic lateral sclerosis	0.000222	0.00584	CbGpPWpGaD
Cladribine—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.000216	0.00354	CcSEcCtD
Cladribine—SLC22A1—central nervous system—amyotrophic lateral sclerosis	0.000216	0.00535	CbGeAlD
Cladribine—NR5A1—Gene Expression—ZNF470—amyotrophic lateral sclerosis	0.000213	0.00561	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	0.000208	0.00546	CbGpPWpGaD
Cladribine—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.000208	0.0034	CcSEcCtD
Cladribine—SLC22A1—Neurotransmitter Release Cycle—CHAT—amyotrophic lateral sclerosis	0.000207	0.00544	CbGpPWpGaD
Cladribine—Rash—Riluzole—amyotrophic lateral sclerosis	0.000206	0.00337	CcSEcCtD
Cladribine—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.000206	0.00337	CcSEcCtD
Cladribine—Headache—Riluzole—amyotrophic lateral sclerosis	0.000205	0.00335	CcSEcCtD
Cladribine—DCK—brain—amyotrophic lateral sclerosis	0.000201	0.00498	CbGeAlD
Cladribine—SLC22A2—Neurotransmitter Release Cycle—SLC6A1—amyotrophic lateral sclerosis	0.000198	0.0052	CbGpPWpGaD
Cladribine—ABCG2—medulla oblongata—amyotrophic lateral sclerosis	0.000195	0.00484	CbGeAlD
Cladribine—RRM2B—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000195	0.00513	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000195	0.00513	CbGpPWpGaD
Cladribine—Nausea—Riluzole—amyotrophic lateral sclerosis	0.000194	0.00318	CcSEcCtD
Cladribine—SLC28A3—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	0.000193	0.00507	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP12—amyotrophic lateral sclerosis	0.00019	0.00498	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000189	0.00496	CbGpPWpGaD
Cladribine—SLC28A3—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	0.000185	0.00487	CbGpPWpGaD
Cladribine—SLC22A1—Neurotransmitter Release Cycle—SLC6A1—amyotrophic lateral sclerosis	0.000185	0.00485	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000183	0.00481	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—SMN1—amyotrophic lateral sclerosis	0.000181	0.00477	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000179	0.00469	CbGpPWpGaD
Cladribine—NR5A1—Generic Transcription Pathway—RARA—amyotrophic lateral sclerosis	0.000177	0.00464	CbGpPWpGaD
Cladribine—ABCG2—spinal cord—amyotrophic lateral sclerosis	0.000174	0.00432	CbGeAlD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	0.000172	0.00453	CbGpPWpGaD
Cladribine—SLC22A1—brain—amyotrophic lateral sclerosis	0.000172	0.00425	CbGeAlD
Cladribine—PNP—Metabolism—VAPB—amyotrophic lateral sclerosis	0.000169	0.00444	CbGpPWpGaD
Cladribine—PNP—Metabolism—TPK1—amyotrophic lateral sclerosis	0.000169	0.00444	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000166	0.00436	CbGpPWpGaD
Cladribine—RRM2B—DNA Damage Response—TP53—amyotrophic lateral sclerosis	0.000165	0.00433	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.000163	0.00428	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.000163	0.00428	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—ZNF746—amyotrophic lateral sclerosis	0.000162	0.00425	CbGpPWpGaD
Cladribine—RRM2B—miRNA Regulation of DNA Damage Response—TP53—amyotrophic lateral sclerosis	0.000159	0.00419	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000156	0.0041	CbGpPWpGaD
Cladribine—PNP—Metabolism—VAPA—amyotrophic lateral sclerosis	0.000155	0.00407	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—RARA—amyotrophic lateral sclerosis	0.000155	0.00406	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—PFN1—amyotrophic lateral sclerosis	0.00015	0.00393	CbGpPWpGaD
Cladribine—RRM1—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000147	0.00385	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	0.000146	0.00383	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—OPTN—amyotrophic lateral sclerosis	0.000146	0.00383	CbGpPWpGaD
Cladribine—PNP—Metabolism—SACM1L—amyotrophic lateral sclerosis	0.000144	0.00378	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—DAO—amyotrophic lateral sclerosis	0.000141	0.00371	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	0.000139	0.00364	CbGpPWpGaD
Cladribine—ABCG2—cerebellum—amyotrophic lateral sclerosis	0.000138	0.00342	CbGeAlD
Cladribine—PNP—Metabolism—FIG4—amyotrophic lateral sclerosis	0.000135	0.00355	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	0.000133	0.0035	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	0.000124	0.00327	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	0.000124	0.00326	CbGpPWpGaD
Cladribine—PNP—Metabolism—DAO—amyotrophic lateral sclerosis	0.000122	0.00321	CbGpPWpGaD
Cladribine—RRM2—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	0.000121	0.00317	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	0.000112	0.00295	CbGpPWpGaD
Cladribine—ABCG2—brain—amyotrophic lateral sclerosis	0.000112	0.00278	CbGeAlD
Cladribine—NR5A1—Gene Expression—HNRNPA1—amyotrophic lateral sclerosis	0.000112	0.00294	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.000109	0.00287	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.000109	0.00287	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	0.000107	0.00282	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PLB1—amyotrophic lateral sclerosis	0.000107	0.00281	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—MAPT—amyotrophic lateral sclerosis	0.000106	0.00279	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	0.000106	0.00278	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	0.000106	0.00278	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	0.000105	0.00276	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	0.000105	0.00276	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—FUS—amyotrophic lateral sclerosis	0.000104	0.00274	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CST3—amyotrophic lateral sclerosis	0.000103	0.00271	CbGpPWpGaD
Cladribine—SLC22A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	0.000101	0.00266	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—EXOSC9—amyotrophic lateral sclerosis	0.000101	0.00265	CbGpPWpGaD
Cladribine—POLE2—G1 to S cell cycle control—TP53—amyotrophic lateral sclerosis	0.000101	0.00265	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GSR—amyotrophic lateral sclerosis	9.87e-05	0.00259	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—OPTN—amyotrophic lateral sclerosis	9.79e-05	0.00257	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	9.79e-05	0.00257	CbGpPWpGaD
Cladribine—RRM1—Metabolism—VAPB—amyotrophic lateral sclerosis	9.72e-05	0.00255	CbGpPWpGaD
Cladribine—RRM1—Metabolism—TPK1—amyotrophic lateral sclerosis	9.72e-05	0.00255	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—IGFBP3—amyotrophic lateral sclerosis	9.71e-05	0.00255	CbGpPWpGaD
Cladribine—SLC22A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A1—amyotrophic lateral sclerosis	9.45e-05	0.00248	CbGpPWpGaD
Cladribine—SLC28A3—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	9.42e-05	0.00247	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	9.4e-05	0.00247	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—OPTN—amyotrophic lateral sclerosis	9.4e-05	0.00247	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	9.31e-05	0.00244	CbGpPWpGaD
Cladribine—PNP—Metabolism—PLB1—amyotrophic lateral sclerosis	9.27e-05	0.00244	CbGpPWpGaD
Cladribine—RRM2B—Direct p53 effectors—TP53—amyotrophic lateral sclerosis	9.26e-05	0.00243	CbGpPWpGaD
Cladribine—POLE—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	8.93e-05	0.00235	CbGpPWpGaD
Cladribine—RRM1—Metabolism—VAPA—amyotrophic lateral sclerosis	8.89e-05	0.00233	CbGpPWpGaD
Cladribine—PNP—Metabolism—GSR—amyotrophic lateral sclerosis	8.56e-05	0.00225	CbGpPWpGaD
Cladribine—NR5A1—Gene Expression—RARA—amyotrophic lateral sclerosis	8.5e-05	0.00223	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	8.41e-05	0.00221	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	8.32e-05	0.00219	CbGpPWpGaD
Cladribine—POLE2—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	8.28e-05	0.00217	CbGpPWpGaD
Cladribine—RRM1—Metabolism—SACM1L—amyotrophic lateral sclerosis	8.27e-05	0.00217	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—CHAT—amyotrophic lateral sclerosis	8.11e-05	0.00213	CbGpPWpGaD
Cladribine—RRM2—Metabolism—TPK1—amyotrophic lateral sclerosis	8e-05	0.0021	CbGpPWpGaD
Cladribine—RRM2—Metabolism—VAPB—amyotrophic lateral sclerosis	8e-05	0.0021	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	7.99e-05	0.0021	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	7.84e-05	0.00206	CbGpPWpGaD
Cladribine—RRM1—Metabolism—FIG4—amyotrophic lateral sclerosis	7.77e-05	0.00204	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	7.76e-05	0.00204	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP9—amyotrophic lateral sclerosis	7.5e-05	0.00197	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	7.5e-05	0.00197	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—TUBA4A—amyotrophic lateral sclerosis	7.49e-05	0.00197	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—OPTN—amyotrophic lateral sclerosis	7.49e-05	0.00197	CbGpPWpGaD
Cladribine—DCK—Metabolism—TPK1—amyotrophic lateral sclerosis	7.48e-05	0.00196	CbGpPWpGaD
Cladribine—DCK—Metabolism—VAPB—amyotrophic lateral sclerosis	7.48e-05	0.00196	CbGpPWpGaD
Cladribine—RRM2—Metabolism—VAPA—amyotrophic lateral sclerosis	7.32e-05	0.00192	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	7.29e-05	0.00191	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	7.24e-05	0.0019	CbGpPWpGaD
Cladribine—RRM1—Metabolism—DAO—amyotrophic lateral sclerosis	7.03e-05	0.00185	CbGpPWpGaD
Cladribine—PNP—Metabolism—CHAT—amyotrophic lateral sclerosis	7.03e-05	0.00185	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	6.99e-05	0.00184	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	6.86e-05	0.0018	CbGpPWpGaD
Cladribine—DCK—Metabolism—VAPA—amyotrophic lateral sclerosis	6.84e-05	0.0018	CbGpPWpGaD
Cladribine—RRM2—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.81e-05	0.00179	CbGpPWpGaD
Cladribine—RRM1—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	6.75e-05	0.00177	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—OPTN—amyotrophic lateral sclerosis	6.69e-05	0.00176	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TUBA4A—amyotrophic lateral sclerosis	6.69e-05	0.00176	CbGpPWpGaD
Cladribine—POLE—G1 to S cell cycle control—TP53—amyotrophic lateral sclerosis	6.5e-05	0.00171	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	6.45e-05	0.00169	CbGpPWpGaD
Cladribine—RRM2—Metabolism—FIG4—amyotrophic lateral sclerosis	6.4e-05	0.00168	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	6.39e-05	0.00168	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	6.38e-05	0.00167	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	6.38e-05	0.00167	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle, Mitotic—DCTN1—amyotrophic lateral sclerosis	6.37e-05	0.00167	CbGpPWpGaD
Cladribine—DCK—Metabolism—SACM1L—amyotrophic lateral sclerosis	6.36e-05	0.00167	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—BDNF—amyotrophic lateral sclerosis	6.32e-05	0.00166	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	6.08e-05	0.0016	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	6.04e-05	0.00159	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PLA2G4A—amyotrophic lateral sclerosis	6.04e-05	0.00159	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	6.01e-05	0.00158	CbGpPWpGaD
Cladribine—DCK—Metabolism—FIG4—amyotrophic lateral sclerosis	5.98e-05	0.00157	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—GRIA2—amyotrophic lateral sclerosis	5.95e-05	0.00156	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	5.94e-05	0.00156	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	5.94e-05	0.00156	CbGpPWpGaD
Cladribine—ABCG2—HIF-2-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	5.83e-05	0.00153	CbGpPWpGaD
Cladribine—RRM2—Metabolism—DAO—amyotrophic lateral sclerosis	5.79e-05	0.00152	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	5.75e-05	0.00151	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—DCTN1—amyotrophic lateral sclerosis	5.69e-05	0.00149	CbGpPWpGaD
Cladribine—SLC22A2—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	5.68e-05	0.00149	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC1A2—amyotrophic lateral sclerosis	5.67e-05	0.00149	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	5.61e-05	0.00147	CbGpPWpGaD
Cladribine—RRM2—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	5.56e-05	0.00146	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—GRIA2—amyotrophic lateral sclerosis	5.54e-05	0.00146	CbGpPWpGaD
Cladribine—DCK—Metabolism—DAO—amyotrophic lateral sclerosis	5.41e-05	0.00142	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	5.36e-05	0.00141	CbGpPWpGaD
Cladribine—POLE—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	5.33e-05	0.0014	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PLB1—amyotrophic lateral sclerosis	5.33e-05	0.0014	CbGpPWpGaD
Cladribine—SLC22A1—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	5.3e-05	0.00139	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—NEFL—amyotrophic lateral sclerosis	5.25e-05	0.00138	CbGpPWpGaD
Cladribine—DCK—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	5.19e-05	0.00136	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	5.17e-05	0.00136	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSR—amyotrophic lateral sclerosis	4.92e-05	0.00129	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—NEFL—amyotrophic lateral sclerosis	4.9e-05	0.00129	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	4.89e-05	0.00128	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—CHAT—amyotrophic lateral sclerosis	4.89e-05	0.00128	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	4.84e-05	0.00127	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC1A3—amyotrophic lateral sclerosis	4.82e-05	0.00127	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	4.79e-05	0.00126	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	4.76e-05	0.00125	CbGpPWpGaD
Cladribine—SLC22A2—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	4.61e-05	0.00121	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	4.55e-05	0.0012	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—CHAT—amyotrophic lateral sclerosis	4.55e-05	0.0012	CbGpPWpGaD
Cladribine—ABCG2—Fluoropyrimidine Activity—TP53—amyotrophic lateral sclerosis	4.51e-05	0.00119	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—TRPM7—amyotrophic lateral sclerosis	4.47e-05	0.00117	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PLB1—amyotrophic lateral sclerosis	4.39e-05	0.00115	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—GSTP1—amyotrophic lateral sclerosis	4.36e-05	0.00114	CbGpPWpGaD
Cladribine—SLC22A2—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	4.35e-05	0.00114	CbGpPWpGaD
Cladribine—SLC22A1—SLC-mediated transmembrane transport—SLC6A1—amyotrophic lateral sclerosis	4.29e-05	0.00113	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—IGF1—amyotrophic lateral sclerosis	4.11e-05	0.00108	CbGpPWpGaD
Cladribine—DCK—Metabolism—PLB1—amyotrophic lateral sclerosis	4.1e-05	0.00108	CbGpPWpGaD
Cladribine—SLC22A1—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	4.06e-05	0.00107	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSR—amyotrophic lateral sclerosis	4.05e-05	0.00106	CbGpPWpGaD
Cladribine—RRM1—Metabolism—CHAT—amyotrophic lateral sclerosis	4.04e-05	0.00106	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	4e-05	0.00105	CbGpPWpGaD
Cladribine—POLA1—Retinoblastoma (RB) in Cancer—TP53—amyotrophic lateral sclerosis	3.8e-05	0.000998	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSR—amyotrophic lateral sclerosis	3.78e-05	0.000993	CbGpPWpGaD
Cladribine—PNP—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.78e-05	0.000992	CbGpPWpGaD
Cladribine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	3.6e-05	0.000945	CbGpPWpGaD
Cladribine—PNP—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.47e-05	0.000912	CbGpPWpGaD
Cladribine—ABCG2—HIF-1-alpha transcription factor network—VEGFA—amyotrophic lateral sclerosis	3.43e-05	0.000901	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—amyotrophic lateral sclerosis	3.4e-05	0.000894	CbGpPWpGaD
Cladribine—RRM2—Metabolism—CHAT—amyotrophic lateral sclerosis	3.32e-05	0.000873	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—APOE—amyotrophic lateral sclerosis	3.29e-05	0.000865	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—MMP9—amyotrophic lateral sclerosis	3.21e-05	0.000842	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—CASP3—amyotrophic lateral sclerosis	3.16e-05	0.00083	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	3.12e-05	0.00082	CbGpPWpGaD
Cladribine—DCK—Metabolism—CHAT—amyotrophic lateral sclerosis	3.11e-05	0.000816	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	3.09e-05	0.000811	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.99e-05	0.000786	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.99e-05	0.000786	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—TPK1—amyotrophic lateral sclerosis	2.96e-05	0.000778	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—VAPB—amyotrophic lateral sclerosis	2.96e-05	0.000778	CbGpPWpGaD
Cladribine—NR5A1—Developmental Biology—VEGFA—amyotrophic lateral sclerosis	2.88e-05	0.000756	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC1A2—amyotrophic lateral sclerosis	2.88e-05	0.000756	CbGpPWpGaD
Cladribine—PNP—Metabolism—APOE—amyotrophic lateral sclerosis	2.86e-05	0.00075	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—VAPB—amyotrophic lateral sclerosis	2.76e-05	0.000725	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—TPK1—amyotrophic lateral sclerosis	2.76e-05	0.000725	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.74e-05	0.000719	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—VAPA—amyotrophic lateral sclerosis	2.71e-05	0.000712	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—VEGFA—amyotrophic lateral sclerosis	2.68e-05	0.000704	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.65e-05	0.000697	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.65e-05	0.000697	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.63e-05	0.00069	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.63e-05	0.00069	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.55e-05	0.000668	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—VAPA—amyotrophic lateral sclerosis	2.53e-05	0.000663	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.52e-05	0.000662	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC1A3—amyotrophic lateral sclerosis	2.45e-05	0.000643	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—AQP4—amyotrophic lateral sclerosis	2.45e-05	0.000643	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.39e-05	0.000629	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—FIG4—amyotrophic lateral sclerosis	2.37e-05	0.000622	CbGpPWpGaD
Cladribine—ABCG2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.37e-05	0.000621	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.35e-05	0.000617	CbGpPWpGaD
Cladribine—SLC22A2—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.34e-05	0.000615	CbGpPWpGaD
Cladribine—RRM2B—Metabolism—PTGS2—amyotrophic lateral sclerosis	2.26e-05	0.000593	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—FIG4—amyotrophic lateral sclerosis	2.21e-05	0.00058	CbGpPWpGaD
Cladribine—SLC22A1—Transmembrane transport of small molecules—SLC6A1—amyotrophic lateral sclerosis	2.18e-05	0.000573	CbGpPWpGaD
Cladribine—RRM1—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.17e-05	0.00057	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—DAO—amyotrophic lateral sclerosis	2.16e-05	0.000568	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—DAO—amyotrophic lateral sclerosis	2.14e-05	0.000563	CbGpPWpGaD
Cladribine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—amyotrophic lateral sclerosis	2.03e-05	0.000532	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—DAO—amyotrophic lateral sclerosis	2e-05	0.000524	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.99e-05	0.000524	CbGpPWpGaD
Cladribine—PNP—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.96e-05	0.000514	CbGpPWpGaD
Cladribine—POLE2—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.91e-05	0.000502	CbGpPWpGaD
Cladribine—RRM2—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.79e-05	0.000469	CbGpPWpGaD
Cladribine—DCK—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.67e-05	0.000438	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.64e-05	0.000431	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.64e-05	0.000431	CbGpPWpGaD
Cladribine—RRM1—Metabolism—APOE—amyotrophic lateral sclerosis	1.64e-05	0.000431	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PLB1—amyotrophic lateral sclerosis	1.62e-05	0.000426	CbGpPWpGaD
Cladribine—DCK—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.53e-05	0.000403	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSR—amyotrophic lateral sclerosis	1.51e-05	0.000398	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PLB1—amyotrophic lateral sclerosis	1.51e-05	0.000397	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSR—amyotrophic lateral sclerosis	1.5e-05	0.000393	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSR—amyotrophic lateral sclerosis	1.4e-05	0.000367	CbGpPWpGaD
Cladribine—RRM2—Metabolism—APOE—amyotrophic lateral sclerosis	1.35e-05	0.000355	CbGpPWpGaD
Cladribine—RRM2—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.28e-05	0.000337	CbGpPWpGaD
Cladribine—DCK—Metabolism—APOE—amyotrophic lateral sclerosis	1.26e-05	0.000331	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.24e-05	0.000326	CbGpPWpGaD
Cladribine—POLE—Cell Cycle—TP53—amyotrophic lateral sclerosis	1.23e-05	0.000323	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—CHAT—amyotrophic lateral sclerosis	1.23e-05	0.000323	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—CHAT—amyotrophic lateral sclerosis	1.15e-05	0.000301	CbGpPWpGaD
Cladribine—RRM1—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.12e-05	0.000295	CbGpPWpGaD
Cladribine—RRM2—Metabolism—PTGS2—amyotrophic lateral sclerosis	9.26e-06	0.000243	CbGpPWpGaD
Cladribine—POLA1—Cell Cycle—TP53—amyotrophic lateral sclerosis	8.77e-06	0.00023	CbGpPWpGaD
Cladribine—DCK—Metabolism—PTGS2—amyotrophic lateral sclerosis	8.65e-06	0.000227	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.68e-06	0.000175	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.61e-06	0.000174	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—GSTP1—amyotrophic lateral sclerosis	6.16e-06	0.000162	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.14e-06	0.000161	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.08e-06	0.00016	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	5.66e-06	0.000149	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—APOE—amyotrophic lateral sclerosis	5.05e-06	0.000133	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—APOE—amyotrophic lateral sclerosis	5e-06	0.000131	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—APOE—amyotrophic lateral sclerosis	4.66e-06	0.000122	CbGpPWpGaD
Cladribine—ABCG2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.46e-06	9.09e-05	CbGpPWpGaD
Cladribine—SLC22A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.43e-06	9e-05	CbGpPWpGaD
Cladribine—SLC22A1—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.19e-06	8.38e-05	CbGpPWpGaD
